Medical Doctor Program year 2024 Source: CMS Open Payments, 2026 publication

Brian Olenslager

Pain Medicine Provo, UT Medical Doctor

NPI 1225036064 CMS profile 455129

3585 N University Ave, Ste 150, Provo, UT 84604

Open in the dashboard

General payments

$25

1 record reported · program year 2024

Research payments

$0

Paid to them · None reported · program year 2024

Ownership & investment interest

$0

None reported

Through program year 2024, Brian Olenslager of Provo, UT is reported in the CMS Open Payments database as having received $25 across 1 general payment and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 3rd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2024 General $25 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Olenslager
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Brian Olenslager were reported at $0. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Brian Olenslager Pain Medicine median Middle half National median
2019 $0 $409 $115–$1,311 $163
2020 $0 $214 $66–$666 $114
2021 $0 $299 $84–$899 $132
2022 $0 $335 $103–$1,149 $149
2023 $0 $376 $114–$1,228 $160
2024 $25 $387 $115–$1,173 $164
2025 $0 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program year 2024
  1. Boston Scientific Corporation $25 1 payment

Every payment, record by record

What the payments were for General payments · program year 2024
  1. Food and Beverage $25 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,918

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$76,614

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

22.4%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 26 $23,177
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 232 $10,961
Pregabalin Generic 301 $9,400
Gabapentin Generic 190 $6,013
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 139 $4,079
Duloxetine Hcl Generic 198 $3,500
Oxycodone Hcl Generic 153 $3,488
Morphine Sulfate Er Morphine Sulfate Brand 33 $2,474
Fentanyl Generic 23 $2,455
Morphine Sulfate Generic 27 $1,783

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$105,652

Of which drugs: $145

Medicare patients

221

Average age 75

Services billed

1,287

136 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Depression 43%
Chronic kidney disease 35%
Diabetes 31%
Ischemic heart disease 24%
Osteoporosis 19%
Heart failure 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 20 164 $122
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 96 255 $23

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record